Translating a radiolabeled imaging agent to the clinic.

Area of Science:

• Radiochemistry
• Nuclear Medicine
• Pharmacology

Background:

• Molecular imaging is rapidly advancing with new agents entering development and clinical use.
• Understanding the comprehensive process for developing these agents is vital for stakeholders.

Purpose of the Study:

• To provide an overview of the development pathway for novel molecular imaging agents.
• To detail the stages from discovery and preclinical validation through clinical trials (Phase 1-3) and regulatory approval.

Main Methods:

• Exemplification using a low molecular weight, disease-specific targeted positron emission tomography (PET) agent.
• Discussion of regulatory considerations and clinical trial phases.
• Overview of post-approval processes for new agents.

Main Results:

• The development pathway includes discovery, preclinical validation, and phased clinical trials (Phase 1, 2, 3).
• Molecular imaging agents, despite low doses, require rigorous evaluation similar to drugs.
• Successful completion can lead to FDA general use approval.

Conclusions:

• The journey of a molecular imaging agent from concept to clinic is complex but well-defined.
• Each stage, from preclinical research to post-approval, is critical for ensuring safety and efficacy.
• This overview serves as a guide for navigating the development and approval of novel imaging agents.